Abstract: Dopamine (DA) receptor and transporter dysfunctions play a major role in the pathophysiology of neuropsychiatric diseases including anxiety disorder (AD), major depressive disorder (MDD), bipolar disorder (BD) in the manic (BD man ) or depressive (BD dep ) state and schizophrenia (SZ). We performed a PUBMED search, which provided a total of 239 in vivo imaging studies with either positron emission tomography (PET) or singleproton emission computed tomography (SPECT). In these studies, DA transporter binding, D 1 receptor (R) binding, D 2 R binding, DA synthesis and/or DA release in patients with the primary diagnosis of acute AD (n = 310), MDD (n = 754), BD man (n = 15), BD dep (n = 49) or SZ (n = 1532) were compared to healthy individuals. A retrospective analysis revealed that AD, MDD, BD man , BD dep and SZ differed as to affected brain region(s), affected synaptic constituent(s) and extent as well as direction of dysfunction in terms of either sensitization or desensitization of transporter and/or receptor binding sites. In contrast to AD and SZ, in MDD, BD man and BD dep , neostriatal DA function was normal, whereas MDD, BD man , and BD dep were characterized by the increased availability of prefrontal and frontal DA. In contrast to AD, MDD, BD man and BD dep , DA function in SZ was impaired throughout the nigrostriatal and mesolimbocortical system with an increased availability of DA in the striatothalamocortical and a decreased availability in the mesolimbocortical pathway.
Introduction
A variety of neurotransmitters have been implied in the pathophysiology of anxiety disorder (AD), major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia (SZ). Among them are serotonin (5-HT; AD, Lowry et al., 2005; MDD, Di Giovanni et al., 2006 ; SZ, Di Pietro and Seamans, 2007 ; BD, Deeks and Keeting, 2008) , acetylcholine (SZ, Hajos and Rogers, 2010 ; BD, McEvoy and Allen, 2002 ; MDD, Mineur and Picciotto, 2010; AD, Graef et al., 2011) , glutamate (AD, Carlsson, 2001 ; SZ, Konradi and Heckers, 2003 ; BD, Lenox and Wang, 2003 ; MDD, Mitchell and Baker, 2010) and γ-aminobutyric acid (GABA; SZ, Taylor and Tso, 2014; AD, Nuss, 2015 ; MDD, Pehrson and Sanchez, 2015; BD, Romeo et al., 2018) .
Furthermore, a pivotal role has been ascribed to dysfunctions of the nigrostriatal and mesolimbic dopamin(DA)ergic pathways (SZ, Seeman and Lee, 1975; MDD, Willner, 1983 ; AD, Stein et al., 2002 ; BD, Deeks and Keeting, 2008) . In the nigrostriatal system, the neostriatum (STR) receives DAergic afferents from the pars compacta of the substantia nigra (SN) and sends DAergic efferents to the thalamus (THAL), neocortex and back to the SN (Afifi, 1994a) . In the mesolimbic system, the ventral striatum (VS) is primarily innervated by DAergic fibers arising from the ventral tegmental area (VTA) and projects to the neocortex and limbic regions including amygdala (AMYG) and hippocampus (HIPP; Afifi, 1994b) .
In recent surveys of all in vivo imaging studies, which, so far, had been conducted on DAergic neurotransmission in acute AD, MDD, BD and SZ using either positron emission tomography (PET) or single-proton emission computed tomography (SPECT) (Nikolaus et al., 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a (Nikolaus et al., ,b, 2016 (Nikolaus et al., , 2017 , we found (1) a significant reduction of DA D 2 receptors (D 2 Rs) in the STR of AD patients relative to controls; (2) increases of DA synthesis in the prefrontal cortex (PFC) and frontal cortex (FC) of MDD patients relative to controls; (3) a reduction of DA D 1 receptors (D 1 Rs) in the FC of acutely manic BD patients (BD man ) relative to controls; (4) a reduction of D 1 Rs in the FC of acutely depressed BD patients (BD dep ) relative to controls; (5) a reduction of DA transporter (DAT) density in the STR, a reduction of D 1 Rs in the STR and reductions of D 2 Rs in STR, THAL, FC and parietal cortex (PC) of SZ patients relative to controls, 47 ± 15; 1568 controls, age: 32 ± 8 years] published in peerreviewed journals between December 2017. In the present analysis, all available in vivo investigations on AD, MDD, BD dep , BD man and SZ patients in the acute stage of disease were enrolled irrespective of their medication state (Tables 1-4 ). The inclusion criterion was that patients with the primary diagnosis of AD, MDD, BD dep , BD man , or SZ had to be compared to healthy controls. Moreover, quantitative data of patients and controls had to be communicated in the original publication.
Data were evaluated as previously described (Nikolaus et al., 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a (Nikolaus et al., ,b, 2016 (Nikolaus et al., , 2017 . Percentual differences of VMAT2, DAT, D 1 R and D 2 R binding as well as DA synthesis and DA release to the respective control groups were calculated for the following brain regions: STR (nucleus caudate, putamen), VS, globus pallidus (GP), THAL, PFC 46, 47, and 49) , FC (PFC plus Brodmann areas 4 and 6), PC (Broadmann areas 3, 5, 7, 8, 39, and 40) , temporal cortex (TC; Brodmann areas 20-22, 38, 41 and 42) , occiptal cortex (OC; Brodmann areas 17-19), cingulate (CING), HIPP, parahippocampal gyrus (PHG), AMYG, insula (INS), mibrain/pons (MB), SN, VTA, locus caeruleus (LC) and cerebellum (CER). Left and right radioactivity accumulations were pooled, if given separately in the original publication. If the authors had analyzed more than one area within STR, PFC, FC, PC, TC, OC and CING, the mean values of these data were calculated for AD, MDD, BD dep , BD man and SZ subjects and the respective controls prior to computing percentual differences.
Statistic calculations were performed with IBM SPSS Statistics 22 (IBM SPSS Software Germany, Ehningen, Germany). The Kolmogorov-Smirnov test for normal distribution could not be performed for a number of variables in the individual disorders, as the sum of weighted cases per disorder and brain region fell short of 5. Hence, medians of percentual differences of VMAT2, DAT, D 1 R and D 2 R binding as well as DA synthesis and DA release in the individual brain regions relative to controls were computed for patients with AD, MDD, BD man , BD dep and SZ. Differences between AD, MDD, BD man , BD dep and SZ patients and the respective controls were assessed with the non-parametric Mann-Whitney U-test (α = 0.05) for independent samples. Furthermore, the individual parameters of synaptic function were compared between disorders (AD vs. MDD, AD vs. BD man , AD vs. BD dep , AD vs. SZ, MDD vs. BD man , MDD vs. BD dep , MDD vs. SZ, BD man vs. SZ or BD dep vs. SZ) with the Mann-Whitney U-test (α = 0.05). No corrections were made for multiple comparisons. As implied by the outcome of our precedent surveys on AD, MDD, BD man , BD dep and SZ (Nikolaus et al., 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a (Nikolaus et al., ,b, 2016 (Nikolaus et al., , 2017 , significance tests were performed one-sidedly. Given are the reference (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligands comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days). Abbreviations (in alphabetical order): α2, 
2017
Same cohorts as Ledermann et al., 2016 BDI: 17 ± 9 MADRS: 16 ± 9 SHPS: 2 ± 1 PDI: 25 ± 7
DArel Given are the reference (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligands comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days DA release ( Figure 5 ) was elevated in the STR (n = 2, +27%, p = 0.051). So far, no investigation of DA synthesis has been conducted on AD patients.
MDD
DAT (Figure 1 ) was diminished in PFC (n = 2, −13%, p = 0.051), FC (n = 2, −13%, p = 0.051), CING (n = 1, −93%, p < 0.05), AMYG (n = 1, −46%, p < 0.05), SN (n = 1, −17%, p < 0.05) and LC (n = 1, −54%, p < 0.05) relative to healthy individuals. Contrarily, DAT binding was unaltered in STR (n = 24), VS (n = 2), THAL (n = 2), PC (n = 1), TC (n = 1), OC (n = 1) and MB (n = 2). D 1 R (Figure 2 ) was reduced in the STR (n = 2, −8%, p = 0.051), but not different from healthy subjects in VS (n = 1), CING (n = 1), AMYG (n = 1) and INS (n = 1). D 2 R (Figure 3 ) was increased in the CING (n = 2, +8%, p = 0.051). No decreases of D 2 R were detected in STR (n = 15), VS (n = 4), THAL (n = 2), FC (n = 1), TC (n = 1), HIPP (n = 1), AMYG (n = 1) and CER (n = 1) relative to controls.
DA synthesis (Figure 4 ) was elevated in PFC (n = 3, +75%, p = 0.017) and FC (n = 3, +75%, p = 0.017), but not different form controls in the STR (n = 5).
DA release ( Figure 5 ) was increased in the VS (n = 1, +7%, p < 0.05), but unaltered in the STR (n = 3). So far, no investigation of VMAT2 binding have been conducted on MDD subjects.
BD man
DAT (Figure 1 ) was elevated relative to controls in the STR (n = 1, +15%, p < 0.05).
D 1 R (Figure 2 ) was dimished in the FC (n = 1, −25%, p < 0.05), but unaltered in the STR (n = 1). Also D 2 R (Figure 3) Dn.s., depression not specified; DRRS, Depression Retardation Raing Scale; ECT, electroconvulsive therapy; EDE, Eating Disorder Examination; f, female; GABA A , GABA A receptor; GAS, Endicott's Global Assessment Scale; H1-4, histamine H1-4 receptor; HAMA, Hamilton Anxiety Scale; HDRS, Hamilton Depression Rating Scale; 5-HT receptor; DAsyn, dopamine synthesis; dep, depressed; DAT, dopamine transporter; f, female; HDRS, Hamilton Depression Rating Scale; m, male; MADRS, Montgomery-Asberg Depression Rating Scale; man, manic; MAOI, monoamine oxidase inhibitor; n, no; n.s., not specified; SHPS, Snaith-Hamilton Pleasure Scale; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressants; TeCA, tetracyclic antidepressants; YMRS, Young Mania Rating Scale. Barnas et al., 2001 Partly the same patients as Küfferle et al., 1996 and Kasper et al., 1998 and the same controls as Küfferle et al., 1996 , Kasper et al., 1998 and Brücke et al., 1991 Partly the same patients as Küfferle et al., 1996 and Kasper et al., 1998 and the same controls as Küfferle et al., 1996 , Kasper et al., 1998 and Barnas et al., 2001 SZ, mania n.s. 
Farde et al., 1990
Same patients as Nordström et al., 1992 Kasper et al., 1998 Partly the same patients as Küfferle et al., 1996 , and Tauscher et al., 1999 and same controls as Küfferle et al., 1996 , Barnas et al., 2001 and Brücke et al., 1991 n.s. Küfferle et al., 1996 Partly the same patients as Kasper et al., 1998 and Küfferle et al., 1997 and same controls as Brücke et al., 1991 and Barnas et al., 2001 Küfferle et al., 1996 , Kasper et al., 1998 , and Tauscher et al., 1999 and same controls as Barnas et al., 2001 , Brücke et al., 1991 , and Küfferle et al., 1996 SZ, SAD 
Laruelle et al., 1996
Partly same patients and controls as Partly same patients and controls as Laruelle et al., 1996 Partly same patients and controls as Laruelle et al., 1996,2000, Laruelle and  et al., 1996, 1999, 2000 Same patients and controls as Laruelle et al., 1996 Partly same patients and controls as Laruelle et al., 1996 
1992
Same patients as Farde et al., 1990 as Pedro et al., 1994 Partly 13/4 17-50 years 3 ± 2 n n.a.
Tauscher et al., 1997
Partly the same controls as Tauscher et al., 1999 , Küfferle et al., 1996 , Kasper et al., 1998 , Barnas et al., 2001 and Brücke et al., 1991 SZ paranoid, Partly the same patients as Küfferle et al., 1997 and Kasper et al., 1998 and partly the same controls as Tauscher et al., 1999 , Küfferle et al., 1996 , Kasper et al., 1998 , Barnas et al., 2001 and Brücke et al., 1991 et al., 1993, 1996 Same controls Psychosis SZ paranoid, undiff.
HDRS: 7 ± 6 MADRS: 10 ± 10 MAPRS: 5 ± 5 YMRS: 18 ± 16 BMRS: 34 ± 32 PPdP: 52 ± 28 PSE: 9 ± 11 n.s. Given are the reference (in alphabetical order), the subtype of disorder, mean rating scale scores (±SD), employed radioligands comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days and DA synthesis (Figure 4) did not differ between patients and healthy individuals in the STR (n = 1, each).
No studies of VMAT2 binding and DA release were available on BD man .
BD dep
DAT (Figure 1) was not different from healthy subjects in the STR (n = 4). D 1 R (Figure 2 ) was lowered in the FC (n = 1, −31%, p < 0.05), but unaltered in the STR (n = 1) relative to healthy controls.
No investigations were available on VMAT2, D 2 R, DA synthesis and DA release in BD dep patients. 
Figure 1: State of in vivo findings on DAT binding in anxiety disorder (AD), major depressive disorder (MDD), the manic state of bipolar disorder (BD man ), the depressive state of bipolar disorder (BD dep ) and schizophrenia (SZ). Considered were 12 studies on AD (155 patients, age: 38 ± 4 years; 170 controls, age: 39 ± 10 years), 22 studies on MDD (343 patients, age: 41 ± 12 years; 546 controls, age: 40 ± 13 years), one study on BD man (one patient, age: 25 years; 10 controls, age: 26 ± 6 years), four studies on BD dep (46 patients, age: 41 ± 1 years; 150 controls, age: 38 ± 2 years) and 11 studies on SZ (184 patients, age: 31 ± 7 years; 134 controls, age: 33 ± 7 years), in which DAT was assessed in neostriatum (STR), ventral striatum (VS), thalamus (THAL), prefrontal cortex (PFC), frontal cortex, (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), cingulate (CING), hippocampus (HIPP), amygdala (AMYG), midbrain/ pons (MB), substantia nigra (SN), locus caeruleus (LC) and cerebellum (CER). The box plots give medians, 25th/75th percentiles (boxes) and 5th/95th percentiles (whiskers) of DAT binding in the investigated brain regions expresssed as percentages of control values. The circles represent the percentages of control values in the individulal investigations (white circles, percentual difference relative to controls not significant in the original investigation; black circles, percentual difference relative to controls significant in the original investigation with a p of at least 0.05). Asteriks indicate significant differences of the pooled samples of AD, MDD, BD dep , BD man or SZ patients relative to the pooled samples of controls or significant differences between pooled samples of AD, MDD BD dep , BD man or SZ (Mann-Whitney U-test, onesided, α = 0.05).
marginally failed to reach statistical significance. No differences to controls were obtained in GP (n = 3), PFC (n = 3), FC (n = 8), PC (n = 2), OC (n = 2), CING (n = 3), HIPP (n = 3), AMYG (n = 2), INS (n = 2), MB (n = 1) and SN (n = 4). DA synthesis (Figure 4 ) was increased in STR (n = 16, +10%, p < 0.001), CING (n = 4, +3%, p = 0.024), AMYG (n = 1, +53%, p < 0.05) and MB (n = 1, +52%, p < 0.05). Moreover, an elevation was observed in the TC (n = 3, +2%, p = 0.061), which marginally failed to reach statistical significance. No differences were found in VS (n = 5), THAL (n = 1), PFC (n = 3), FC (n = 4), PHG (n = 1), SN (n = 1), VTA (n = 1) and CER (n = 1).
DA release ( Figure 5 ) was elevated in STR (n = 10, +80%, p < 0.001) and VS (n = 2, +43%, p = 0.051).
No alterations were observed in THAL (n = 1), PFC (n = 1), FC (n = 1), PC (n = 1), TC (n = 1), CING (n = 1), PHG (n = 1), AMYG (n = 1), INS (n = 1), SN (n = 2) and VTA (n = 1).
So far, no investigation of VMAT2 has been conducted on SZ.
Comparison between disorders DAT
DAT (Figure 1 ) was lowered in the STR (−17%, p = 0.051) of SZ patients relative to BD man . There were no differences Considered were 1 study on AD (seven patients, age: 40 ± 14 years; seven controls, age: 40 ± 12 years), two studies on MDD (28 patients, age: 37 ± 9 years; 14 controls, age: 36 ± 7 years), one study on BD man (1 patient, age: 37 years; 29 controls, age: 20-72 years), one study on BD dep (one patient, age: 37 years; 21 controls, age: 20 -72 years) and eight studies on SZ (98 patients, age: 33 ± 9 years; 113 controls, age: 32 ± 6 years), in which D 1 R were assessed in neostriatum (STR), ventral striatum (VS), thalamus (THAL), prefrontal cortex (PFC), frontal cortex, (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), cingulate (CING), hippocampus (HIPP), parahippocampal gyrus (PHG), amygdala (AMYG) and insula (INS Considered were 11 studies on AD (128 patients, age: 33 ± 5 years; 121 controls, age: 31 ± 4 years), 18 studies on MDD (242 patients, age: 42 ± 7 years; 248 controls, age: 41 ± 10 years), one study on BD man (13 patients, age: 33 ± 12 years; 24 controls, age: 32 ± 12 years) and 68 studies on SZ (1068 patients, age: 32 ± 8 years; 1018 controls, age: 32 ± 9 years), in which D 2 R were assessed in neostriatum (STR), ventral striatum (VS), globus pallidus (GP), thalamus (THAL), prefrontal cortex (PFC), frontal cortex, (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), cingulate (CING), hippocampus (HIPP), amygdala (AMYG), insula (INS), midbrain/pons (MB), substantia nigra (SN) and cerebellum (CER). The box plots give medians, 25th/75th percentiles (boxes) and 5th/95th percentiles (whiskers) of D 2 R binding in the investigated brain regions expresssed as percentages of control values. The circles represent the percentages of control values in the individulal investigations (white circles, percentual difference relative to controls not significant in the original investigation; black circles, percentual difference relative to controls significant in the original investigation with a p of at least 0.05). Asteriks indicate significant differences of the pooled samples of AD, MDD, BD man or SZ patients relative to the pooled samples of controls or significant differences between pooled samples of AD, MDD, BD man or SZ (Mann-Whitney U-test, one-sided, α = 0.05). Considered were six studies on MDD (65 patients, age: 43 ± 5 years; 67 controls, age: 40 ± 7 years), one study on BD man (13 patients, age: 33 ± 12 years; 13 controls, age: 32 ± 12 years), and 14 studies on SZ (152 patients, age: 37 ± 8 years; 190 controls, age: 31 ± 10 years), in which DA synthesis was assessed in neostriatum (STR), ventral striatum (VS), thalamus (THAL), prefrontal cortex (PFC), frontal cortex, (FC), temporal cortex (TC), cingulate (CING), hippocampus (HIPP), parahippocampal gyrus (PHG), amygdala (AMYG), midbrain/pons (MB), substantia nigra (SN), ventral tegmental area (VTA) and cerebellum (CER). The box plots give medians, 25th/75th percentiles and 5th/95th percentiles of the individual synaptic constituents in the investigated brain regions expresssed as percentages of control values. The box plots give medians, 25th/75th percentiles (boxes) and 5th/95th percentiles (whiskers) of DA synthesis in the investigated brain regions expresssed as percentages of control values. The circles represent the percentages of control values in the individulal investigations (white circles, percentual difference relative to controls not significant in the original investigation; black circles, percentual difference relative to controls significant in the original investigation with a p of at least 0.05). Asteriks indicate significant differences of the pooled samples of MDD, BD man or SZ patients relative to the pooled samples of controls or significant differences between pooled samples of MDD, BD man or SZ (Mann-Whitney U-test, one-sided, α = 0.05). (Table 5; Nikolaus et al., 2014b Nikolaus et al., , 2016 .
(STR), BD man and SZ (STR

Discussion
Role of neurotransmitters in neuropsychiatric disorders
It is known that GABA exerts inhibitory effects on both DA ( Grace and Bunney, 1979) and 5-HT neurons (Luparini et al., 2004) . Moreover, DA inhibits the release of GABA (Girault et al., 1986) and 5-HT (Ferre et al., 1994) via D 2 R action. 5-HT, in turn, stimulates the release of both DA Meltzer, 1995, 2000) and GABA ( Cozzi and Nichols, 1996) via 5-HT 1/2 R and 5-HT 2 R, respectively.
On the basis of these interactions, it may be hypothesized that, in AD, the initial deficit is either the abnormal elevation of DA in the STR or the elevation of GABA throughout the nigrostriatal/mesolimbocortical system. If the abundant release of neostriatal DA occurs first in order, neostriatal DA levels are bound to be elevated Considered were 2 studies on AD [20 patients, age: not specified (n.s.); 22 controls, age: n.s.], three studies on MDD (30 patients, age: 36 ± 0.2 years; 38 controls, age: 29 ± 2 years), and 10 studies on SZ (113 patients, age: 32 ± 6 years; 133 controls, age: 32 ± 6 years), in which DA release was assessed in neostriatum (STR), ventral striatum (VS), thalamus (THAL), prefrontal cortex (PFC), frontal cortex, (FC), parietal cortex (PC), temporal cortex (TC), cingulate (CING), parahippocampal gyrus (PHG), amygdala (AMYG), insula (INS), substantia nigra (SN) and ventral tegmental area (VTA). The box plots give medians, 25th/75th percentiles (boxes) and 5th/95th percentiles (whiskers) of DA release in the investigated brain regions expresssed as percentages of control values. The circles represent the percentages of control values in the individulal investigations (white circles, percentual difference relative to controls not significant in the original investigation; black circles, percentual difference relative to controls significant in the original investigation with a p of at least 0.05). Asteriks indicate significant differences of the pooled samples of AD, MDD or SZ patients relative to the pooled samples of controls or significant differences between pooled samples of AD, MDD or SZ (Mann-Whitney U-test, one-sided, α = 0.05). (as DAT density in this region is normal), leading to the observed desensitization of D 1 R and D 2 R in STR and VS. DA inhibits the release of GABA and 5-HT via D 2 R action (Girault et al., 1986; Ferre et al., 1994) . Hence, the desensitization of striatal D 2 heteroreceptors incurs, for one, the elevation of GABA concentrations in the STR as well as in the projection areas of striatothalamocortical GABAergic neurons, which is consistent with the detected desensitization of GABA A R in STR, FC, TC, OC, CING, AMYG, INS and EC of AD patients. Secondly, also 5-HT levels are likely to be augmented, which is consistent with the observed desensitization of SERT in MB, THAL, HT and AMYG, of 5-HT 1 R in MB, PFC, FC, TC, CING, HIPP, PHG, AMYG, INS and FG and of 5-HT 2 R in the VS. If, however, the elevation of GABA constitutes the initial deficit, the likely consequence, for one, is the observed desensitization of GABA A R throughout the nigrostriatal and mesolimbocortical system. Since GABA exerts inhibitory effects on both DA ( Grace and Bunney, 1979) and 5-HT neurons (Luparini et al., 2004) , the desensitization of GABA A R in striatal, neocortical and limbic regions, secondly, diminishes the inhibitory GABAergic input to DA and 5-HT neurons leading to an elevation of both DA and 5-HT concentrations throughout the nigrostriatal/mesolimbocortical system (as reflected by the desensitizations of D 1 R, D 2 R and 5-HT 1 R). Likely, an important role may be ascribed to the PHG, which displays an elevation of GABA A R binding sites, indicative of GABA shortage in this region (see below).
DA and 5-HT concentrations are regulated by autoreceptors of the D 2 R and 5-HT 1 R subtype, respectively, which are localized at the presynaptic terminal and modulate neurotransmitter synthesis and release via inhibitory feedback loops (for a review see Chiodo et al., 1995) . Thus, irrespective to the site of primary neurochemical dysfunction, the desensitizations of inhibitory D 2 autoreceptors in STR and VS and 5-HT 1 autoreceptors in MB, PFC, FC, TC, CING, HIPP, PHG, AMYG, INS and FG reduce feedback inhibition, resulting in a further enhancement of DA efflux in STR/VS and of 5-HT efflux in mesencephalic, neocortical, cingulate and limbic regions.
The desensitization of D 1 , D 2 , 5-HT 1 and 5-HT 2 heteroreceptors in the respective regions may be conceived to reflect adaptive responses to the increased availability of monoamines. Firstly, the desensitization of D 1 heteroreceptors in the STR can be surmised to lead to a compensatory decline of excitatory input to the nigral, neocortical and limbic target regions of descending and ascending projections. Secondly, the desensitization of D 2 heteroreceptors in STR and VS is likely to reduce also the inhibitory input to the nigral, ventral tegmental, neocortical and limbic target regions of descending and ascending DAergic projections. Thirdly, since 5-HT 1 R stimulate the release of DA Meltzer, 1995, 2000) , the desensitization of 5-HT 1 heteroreceptors in MB, neocortex and limbic system likely induces an adaptive reduction of DA efflux in these regions. As, however, so far, no in vivo imaging studies have been conduced on DA synthesis and DA release in MB, neocortex and limbic system, further investigations are required to either confirm or refute this hypothesis. Fourthly, the desensitization of 5-HT 1 heteroreceptors in MB, neocortex and limbic system presumably reduces the inhibitory input to the target regions of descending and ascending 5-HTergic projections.
While excitatory D 1 R and inhibitory D 2 R both are desensitized in the STR, excitatory 5-HT 2 R (in contrast to 5-HT 1 R) is unaltered throughout most part of the neocortex with a significant elevation in the TC (Nikolaus et al., 2016) . The sensitization of temporal 5-HT 2 R may ultimately constitute an adaptive response to the desensitization of 5-HT 2 R in the VS, as the latter may be assumed to reduce not only ventrostriatal excitation but also the net excitatory input to the target regions of ascending 5-HTergic fibers. Due to the small number of investigations, the observation of both decreased 5-HT 2 R in the VS (n = 1) Displayed are significant increases (↑), significant decreases (↓) or no alterations (=) relative to healthy controls as obtained from the present and previous analyses (Nikolaus et al., 2014a (Nikolaus et al., ,b, 2016 in the following brain regions: neostriatum (STR), ventral striatum (VS), globus pallidus (GP), hypothalamus (HT), thalamus (THAL), prefrontal cortex (PFC), frontal cortex (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), cngulate (CING), hippocampus (HIPP), parahippocampal gyrus (PHG), amygdala (AMYG), insula (INS), fusiform gyrus (FG), entorhinal cortex (EC), midbrain /pons (MB), substantia nigra (SN), ventral tegmental area (VTA), locus caeruleus (LC), periaqueductal gray (PAG), cerebellum (CER). and increased 5-HT 2 R in the TC (n = 2), however, must be viewed with caution. Yet, it can not be dismissed that the alterations of excitatory 5-HTergic actions relative to controls may be related to the role of the TC and its limbic connections in self-awareness (for a review see Chavoix and Insausuti, 2017) and emotional learning and memory (for a review see Grosso et al., 2015) , functions, which are presumably disturbed in acute AD. Taken together, the condition of acute AD is characterized by an abundance of neo -and ventrostriatal DA, mesencephalic, thalamic/hypothalamic, cingulate, neocortical (PFC, FC, TC) (Table 5; Nikolaus et al., 2014b Nikolaus et al., , 2016 .
The observed desensitizations of 5-HT 1 R and 5-HT 2 R in MB, CING, PFC, FC, OC, INS and FG may be interpreted to reflect an increased availability of 5-HT in these regions. 5-HT synthesis is not different from healthy controls in STR, THAL and PFC, but diminished in FC, TC and CING (Nikolaus et al., 2016) . As no impairment of GABA A R function and even a sensitization of CING D 2 R has been detected, no effect of D 2 R or GABA A R desensitization on 5-HT levels can be inferred. Rather, the extensive reduction of SERT in MB, STR, THAL, PFC and AMYG implies that SERT hypofunction constitutes the initial deficit in MDD, leading to an abundance of 5-HT throughout the mesolimbocortical system. This is underlined by genetic studies, which show an association between polymorphisms of the SERT gene SLC6A4 and the risk to develop depression and suicidality (Ho et al., 2013) . In the THAL, the finding of SERT desensitization is opposed to the finding of 5-HT 2 R sensitization, which, in contrast, reflects a decreased availability of 5-HT. Thereby, it must be borne in mind that -although pooling of the available studies on thalamic SERT binding has yielded a median reduction -the findings obtained in the individual studies had been widely discrepant, showing increases, decreases or no alteration relative to controls (Nikolaus et al., 2016) . As the finding of thalamic 5-HT 2 R sensitization was obtained in merely one study, further investigations are needed to determine the exact role of of thalamic 5-HT in MDD. So far, the most likely solution of the present contradiction is that thalamic 5-HT 2 R sensitization occurs in a subset of patients displaying a sensitization of the thalamic SERT, leading to increased neurotransmitter reuptake into the presynaptic terminal and subsequent 5-HT shortage.
Corresponding to AD, the desensitization of mesencephalic 5-HT 1 autoreceptors reduces feedback inhibition, resulting in an enhancement of 5-HT release and a further augmentation of mesencephalic 5-HT levels. Contary to AD, however, the desensitization of 5-HT 1 R is confined to the MB and does not involve frontal, cingulate and limbic regions. Thus, in MDD, there is no adaptive reduction of inhibitory neurotransmission in these areas. Rather, limbic inhibition is enhanced via sensitization of 5-HT 1 heteroreceptors in the PHG, with the sensitization of 5-HT 1 autoreceptors additionally reducing parahippocampal 5-HT efflux. This indicates entirely different routes of cognitive and emotional processing in AD and MDD. Thereby, in either disorder, a relevant role may be played by the PHG, which is relevant for processing contextual associations (for a review see Aminoff et al., 2013) , and displays sensitizations of 5-HT 1 R in MDD and GABA A R in AD. A further compensation of 5-HT abundance is achieved in MDD by the desensitization of 5-HT 2 R in CING, PFC, FC, OC INS and FG (none of which is present in AD), leading to a decline of excitatory neocortical, cingulate and limbic neurotransmission.
As 5-HT 2 R is desensitized in CING, PFC, FC, OC, CING, INS and FG, the consequence ought to be a reduction of DA efflux in these regions. DA synthesis and DA release, however, are increased in PFC/FC and VS, respectively, implying augmented DA concentrations, and, thusly, an increase of DA action in the desending and ascending projections of the mesolimbocortical system. Interestingly, in line with SERT hypofunction in the MB, DAT is desensitized in PFC, FC, CING and AMYG, leading to a further increase of DA availability in prefrontal/frontal, cingulate and limbic regions. Possibly, the enhancement of DA synthesis in PFC/FC and of DA release in the VS, together with the desensitization of DAT in PFC/FC, CING and AMYG constitute adaptive responses, aiming to maintain (or even enhance) mesolimbocortical DA function. Thereby, the desensitization of DAT in the SN is likely to incur an elevation of nigral DA to some level, which may eventually account for the normality of DA synthesis, DA release, DAT and D 2 R function in the STR.
MDD patients display a desensitization of striatal D 1 R. As the striatal D 2 R density is not different from controls, this can not be interpreted in terms of an adaptive response to an abundance of striatal DA. Rather, due to the higher expression of D 1 R relative to D 2 R in neocortical tissues (Palacios et al., 1988) , the elevation of prefrontal/ frontal DA levels is likely to induce a net increase of excitatory action in the descending fibers of the nigrostriatal and mesolimbocortical pathways, which requires compensation by the observed desensitization of striatal D 1 R.
D 2 R is sensitized in the CING, which reflects DA shortage. Since 5-HT stimulates DA efflux via 5-HT 1/2 R ( Meltzer, 1995, 2000) , an association can be inferred between the desensitization of 5-HT 2 R in the CING and the implied reduction of DA. The assumption of DA shortage, however, is not consistent with the normal D 1 R binding in the CING, although the latter finding must be viewed with reserve, since it was obtained in merely one investigation. As the CING is relevant for the processing of emotion and social behavior (for a review see Hadland et al., 2003) , further investigations are required to elucidate the exact role of cingulate 5-HT and DA function in MDD, and, for that matter, also AD and BD, on which in vivo studies of CING D 2 R binding are completely lacking.
Taken together, MDD is characterized by an abundance of ventrostriatal and prefrontal/frontal DA and mesencephalic, neostriatal, thalamic, cingulate, prefrontal/ frontal, insular and fusiform 5-HT, while striatal DA and mesencephalic GABA levels are normal. Sensitization and desensitization mechanism likely result in a net reduction of excitatory DA and 5-HT action. Arguably, the initial deficit is SERT hypofunction. As, however, findings on GABA A R function are limited to MB and OC, further investigations are needed to clarify the exact role of GABA A R in acute MDD.
BD
BD man patients displayed an increase of DAT in the STR and a reduction of D 1 R in the FC. In addition, previous analyses had revealed an increase of SERT in the MB as well as decreases of 5-HT 2 R in FC, PC, TC, OC, INS and FG (Nikolaus et al., 2016, 2017) .
BD dep patients showed a decrease of D 1 R in the FC, while precedent analyses had additionally evidenced a decrease of SERT in VS and HIPP, an increase of SERT in CING and INS, and increases of 5-HT 1 R in PFC, FC, HIPP, PHG and AMYG (Nikolaus et al., 2016, 2017) . GABA A R binding, so far, has neither been assessed in BD man nor in BD dep (Table 5) .
In BD man , striatal DA synthesis, D 1 R and D 2 R are not different from healthy controls. Strikingly, however, frontal D 1 R is diminished, which -contrary to AD, but similar to MDD -reflects an increased availability of frontal DA.
So far, studies on 5-HT synthesis and GABA A R are lacking in BD man . However, the desensitization 5-HT 2 R in FC, PC, TC, OC, INS and FG may be interpreted as an adaptive response to the enhanced availability of 5-HT in neocortical and limbic target regions of ascending 5-HTergic fibers. In line with this assumption, the sensitization of MB SERT may be conceived as an adaptation to elevated 5-HT concentrations at the site of origin of ascending 5-HTergic neurons.
Since 5-HT stimulates DA release via 5-HT 1/2 R (Ichikawa and Meltzer, 1995 and Meltzer, , 2000 , the desensitization of these binding sites in the neocortex can be assumed to (though not effectively) diminish cortical DA concentrations and -together with the desensitization of frontal D 1 R -to reduce the (excitatory) DAergic input to the mesolimbic target regions of descending DA neurons (Nikolaus et al., 2017) . Interestingly, striatal DAT is augmented in BD man , reflecting an increased availability of DA in this region. Although this finding must be viewed with caution, since it was obtained in merely one investigation, it may not be excluded that the elevation of DAT density constitutes the very mechanism granting normal striatal DA levels and normal D 1 R and D 2 R binding.
Similar to BD man , striatal D 1 R does not differ between BD dep and healthy controls, whereas frontal D 1 R is diminished, suggesting increased availability of frontal DA also in BD dep . In BD dep , SERT is decreased in VS and HIPP, which reflects diminshed levels of mesolimbic 5-HT. Interestingly, however, SERT binding is increased in CING and INS (implying high 5-HT), whereas both cingulate and insular 5-HT 1 auto-and hetereorecetor binding are normal. It is striking that, also in MDD, SERT binding is elevated in the INS (in contrast to the AMYG), while insular 5-HT 1 auto-and hetereorecetor binding is unaltered relative to healthy controls (Nikolaus et al., 2016) . This, possibly, indicates that the INS (and in BD dep also the CING) contain a higher basal amount of 5-HT than VS, HIPP and AMYG in BD dep and MDD, which, via increased sensitization of the SERT, is effectively transported back into the presynaptic terminals.
The relative shortage of 5-HT in VS and HIPP may incur a reduction of 5-HTergic input to the neocortical and limbic target regions of mesolimbic projections, which likely results in the observed sensitization of inhibitory prefrontal/frontal and limbic 5-HT 1 heteroreceptors, ultimately enhancing the inhibitory input to the target regions of prefrontal/frontal and limbic projections. As 5-HT stimulates DA release via 5-HT 1/2 R action Meltzer, 1995, 2000) , the sensitization of frontal 5-HT 1 R also in BD dep will lead to an augmentation of DA release, entailing the observed desensitization of frontal D 1 R. Yet, on the other hand, the sensitization of inhibitory 5-HT 1 autoreceptors in prefrontal/frontal cortex and limbic system increases the inhibitory action of the negative feedback loop, secondarily leading to a further aggravation of 5-HT shortage.
Taken together, both BD man and BD dep are characterized by elevated frontal DA. However, increased mesencephalic, limbic (INS, FG) and frontoparietotemporooccipital 5-HT underlie the condition of BD man , whereas BD dep patients display decreased prefrontal/frontal and mesolimbic 5-HT levels. Notably, different neocortical and limbic regions are involved in BD man and BD dep . The abundance of 5-HT in BD man may be either due to increased 5-HT synthesis (which, so far, has not been assessed in vivo imaging studies) or to still insufficient sensitization of SERT. Another cause might be a persistent desensitization of 5-HT 1 autoreceptors, which, however, warrants further investigation in in vivo imaging studies. In turn, the shortage of prefrontal and limbic 5-HT in BD dep may be either due to reduced 5-HT synthesis or to a persistent 5-HT 1 autoreceptor sensitization, either of which is still awaiting further in vivo assessment.
SZ
SZ patients showed reductions of DAT in the STR, increases of D 1 R in VS, PFC, FC, PC and OC, reductions of D 2 R in STR, THAL, TC and MB, increases of DA synthesis in STR, CING, AMYG and MB as well as increases of DA release in STR and VS. Furthermore, previous analyses had yielded reductions of 5-HT 1 R in TC, OC, MB and AMYG, reductions of 5-HT 2 R in FC, TC and OC as well as reductions of GABA A R in FC and TC (Table 5 ; Nikolaus et al., 2014b Nikolaus et al., , 2016 .
Given the known association between SZ and variations of the GABA A R gene (Cherlyn et al., 2010) , it may be hypothesized that defects of the GABA A R gene -and, thus, of GABA A R dysfunction -constitute the initial deficit in SZ with a decrease of GABA A R density in FC and TC lowering the inhibitory input to the target regions of descending corticothalamostriatal projections. The likely consequence would be the abundance of DA and 5-HT as reflected by the the observed augmentation of DA synthesis and release in MB, STR, VS, CING and AMYG as well as by the desensitizations of D 2 R in STR, THAL and TC, 5-HT 1 R in TC, OC, MB and AMYG and 5-HT 2 R in FC, TC and OC. On the other hand, it may be argued that the initital deficit in SZ, rather, is excess DA synthesis (in STR, MB, CING and AMYG) and DA release (in STR and VS), leading to the increased availability of DA in the striatothalamocortical pathway and the observed desensitization of D 2 R in STR, THAL, TC and MB. Thereby, the desensitization of inhibitory D 2 autoreceptors in STR, THAL, TC and MB will reduce the feedback inhibition, ultimately leading to a further enhancement of DA release, while the desensitization of D 2 hetereoreceptors will result in the reduction of inhibitory input to the target regions of ascending and descending DAergic fibers.
As D 2 R inhibit the release of GABA and 5-HT (Girault et al., 1986; Ferre et al., 1994) , a further consequence of D 2 R desensitization will be an augmentation of GABA efflux in the neocortical projection areas of ascending GABAergic neurons, which is consistent with the observed desensitization of GABA A R in FC and TC.
Also 5-HT levels are likely to be increased, which is in agreement with the observed desensitizations of 5-HT 1 R in MB, TC, OC and AMYG and of 5-HT 2 R in FC, TC and OC. Thereby, for one, the desensitization of 5-HT 1 autoreceptors in MB, TC, OC and AMYG will disinhibit the feedback loop, resulting in a further enhancement of 5-HT efflux in mesencephalic, neocortical and limbic regions. Secondly, the desensitization of 5-HT 1 and 5-HT 2 heteroreceptors will lead to a compensatory reduction of both inhibitory and excitatory action in the target regions of ascending and descending 5-HT neurons. Thirdly, the desensitization of 5-HT 1/2 R sites in the neocortex, can be assumed to diminish DA concentrations in the neocortex and in the ventrostriatal target region of descending DAergic projections, which is consistent with the detected sensitization of D 1 R in VST, PFC, FC, PC and OC. Strikingly, the sensitization of D 1 R in VST, PFC, FC, PC and OC, as opposed to the desensitization of D 2 R in STR, THAL, TC and MB, implies regional differences of DA levels in SZ, with an increased availability in the striatothalamocortical and a decreased availability in the mesolimbocortical pathway. Similarly, findings in MDD had evidenced regional differences in 5-HT levels, with an increased availability in MB, CING and neocortex but a decreased availability in the PHG. Precedent analyses (Nikolaus et al., 2014b (Nikolaus et al., , 2016 (Nikolaus et al., , 2017 (Nikolaus et al., 2016) . 8. In AD, 5-HT 2 R is desensitized in the VS and sensitized in the TC. In MDD, 5-HT 2 R desensitization is evident in CING, PFC, FC, OC, INS and FG. Moreover, a sensitization of 5-HT 2 R is observed in the THAL. In BD man , 5-HT 2 R desensitization is evident in INS, FG and throughout the whole neocortex. In SZ, 5-HT 2 R desensitization does not involve CING and the limbic system, but is confined to the neocortex (FC, TC, OC). 5-HT 2 R is increased in the TC of AD compared to MDD patients, and in the FC and TC of AD compared to SZ patients. Furthermore, 5-HT 2 R is elevated in the FC of MDD compared to SZ patients (Nikolaus et al., 2016) . 9. In AD, GABA A R is desensitized in STR, CING, FC, TC, OC, AMYG, INS and EC and sensitized in the PHG. In contrast, in SZ, GABA A R desensitization is confined to the neocortex (FC, TC), whereas, in MDD, GABA A R is normal. In AD patients, GABA A R is lower in the AMYG relative to SZ. Moreover, in MDD, occipital GABA A R binding is higher relative to both AD and SZ (Nikolaus et al., 2014b) .
From this may be inferred that striatal DA synthesis is higher and that prefrontal/frontal DA synthesis is lower in SZ relative to MDD. This underlines our conclusion that, in MDD, DA levels are normal in the STR, but abundant in PFC/FC. This also holds for BD man and BD dep . On the other hand, an increased availability of neostriatal DA can be inferred for SZ (relative to both AD and MDD) . Thereby, DA function in SZ is impaired throughout the nigrostriatal and mesolimbocortical system with an increased availability of DA in the striatothalamocortical and a decreased availability in the mesolimbocortical pathway. Striatal DAT binding is higher in BD man than in SZ. This implies that the elevation of DA reuptake may constitute the mechanism, which grants normal neostriatal DA levels as well as normal neostriatal D 1 R and D 2 R binding in BD man . Moreover, neostriatal D 2 R binding is lower in AD relative to MDD and BD man , which indicates different roles of D 2 R auto-and heteroreceptor function in the individual disorders.
Mesencephalic 5-HT levels are increased in AD, MDD, BD man and SZ, but normal in BD dep . Furthermore, AD, MDD, BD man and SZ share the feature of elevated neocortical 5-HT, which, however, in BD man is more extensive, involving the whole frontoparietotemporooccipital cortex. In contrast, BD dep is characterized by a decrease of prefrontal/frontal and limbic 5-HT. Strikingly, in MDD, the desensitization of MB 5-HT 1 auto-and heteroreceptors is concurrent with a sensitization of parahippocampal 5-HT 1 R. This corresponds to the increase of 5-HT 1 R in limbic regions of BD dep patients. Hence, the same line of events -sensitization of limbic 5-HT 1 heteroreceptors leading to an increase of inhibitory input, and sensitization of limbic 5-HT 1 autoreceptors leading to a decline of 5-HT levels -may be assumed to occur in both disorders. However, in MDD, an interaction of limbic and mesencephalic 5-HT function can be inferred, which is is not present in BD dep . Moreover, contrary to AD and SZ, the desensitization of 5-HT 1 R in MDD is confined to the MB and does not involve neocortical, cingulate and limbic regions. Thus, contrary to AD and SZ, in MDD, there is no adaptive reduction of inhibitory neurotransmission in these areas. It is striking that AD is characterized by the highest temporal 5-HT 2 R binding and the lowest cingulate and frontal 5-HT 1 R binding relative to MDD and SZ. Moreover, AD patients display the lowest GABA A R binding in the AMYG relative to SZ, which implies a specific role of excitation in temporal and inhibition in cingulate/limbic and frontocortical regions.
Although the conjecture of region-specific alterations of VMAT2, DAT, D 1 R, D 2 R, DA synthesis and DA release is intriguing, it must be put into perspective: for one, investigations of several parameters of synaptic function are scarce in individual diseases with merely one study of VMAT2 in AD (Table 1) , one study on D 1 R in AD (Table 1) , two studies on D 1 R in MDD (Table 2) , three studies on DA release in MDD (Table 2) , one study on D 1 R in BD man (Table  3) , one study on D 1 R in BD dep (Table 3) , one study on D 2 R in BD man (Table 3) and one study on DA synthesis in BD man (Table 3) . Moreover, so far, no study has been conducted on VMAT2 in MDD, BD man , BD dep and SZ, DA synthesis in AD and DA synthesis in BD man and BD dep . In numerous cases, furthermore, the number of available studies per brain region is limited (Figures 1-5) . If, in addition, the number of investigated subjects is comparatively small, findings are difficult to interpret as to their portability.
Furthermore, as illustrated by Figures 1-5 , the individual findings underlying the obtained differences between AD, MDD, BD man , BD dep , and SZ patients and the respective controls were rather inconsistent with reports of no alterations and both significant and non-significant increases as well as decreases of DAT, D 1 R, D 2 R, DA synthesis and DA release. Thereby, inconsistent findings may be due to varying subtypes of the respective disorders, varying comorbidities, varying disease durations and varying disease severities, which, in addition, have been assessed with a variety of different inventories (Tables 1-4) . Additional factors, which may influence the outcome of studies, are differences in methodology: results can not be expected to be entirely consistent, when they were acquired with different imaging tools such as SPECT and the higher-resolving PET, and with quantification methods ranging from the determination of ratios to cerebellar or cortical reference regions over compartmental modeling to statistical parametric mapping of distribution volumes. In addition, the employment of various radioligands for a given binding site may not only bias (semi)quantitative values due to differences in affinities, but also due to the pitfalls inherent to the respective imaging modality such as the lack of exact attenuation correction in SPECT in conjunction with the usage of specific reconstruction algorithms Bullich et al., 2010) .
Another important issue is the fact that in the majority of original investigations patients had undergone previous and/or current treatment with anticonvulsants, anxiolytics, antidepressants and neuroleptics, actingamong others -on sodium channels and pre-and postsynaptic DA, 5-HT, noradrenaline and GABA binding sites (Tables 1-4) .
Therefore, future in vivo imaging studies are required, which address individual parameters of neurotransmitter function in unmedicated or -preferably -medicationnaïve patients with the primary (and preferably exclusive) diagnosis of individual subtypes of AD (obsessive-compulsive disorder, panic disorder, phobia, etc.), MDD (melancholic, atypical, catatonic depression, seasonal affective disorder, etc.), BD (bipolar I, bipolar II, etc.) in either the manic or depressed state or SZ (paranoid, disorganized, catatonic, etc.) . This especially pertains to brain regions, which are known to play a major role in the mediation of cognition, emotion and social functioniong such as HIPP (for a review see Eichenbaum, 2017) , PHG (for a review see Aminoff et al., 2013) , AMYG (for a review see Gothard et al., 2018) , CING (for a review see Hadland et al., 2003) , TC (for a review see Grosso et al., 2015) and PFC (for a review see Hiser and Koenigs, 2018) . A variety of these regions displayed interesting disease-specific alterations of transporter and receptor binding in individual disorders, such as the elevation of temporal 5-HT 2 R in AD, insular SERT in MDD and BD dep , mesencephalic SERT in BD man , parahippocampal 5-HT 1 R in MDD or cingulate D 2 R in MDD. Noteworthy are, furthermore, the increase of inhibitory prefrontal/frontal and limbic 5-HT 1 R in BD man and excitatory ventrostriatal prefrontal/frontal and parietooccipital D 1 R in SZ, which exemplify that entirely different modes of neurotransmitter action -in this case, increased prefrontal/frontal and limbic 5-HTergic inhibition in BD man as opposed to increased mesolimbocortical DAergic excitation in SZ -may underlie the individual pathological conditions. Besides, there is evidence that neurotransmitters beyond DA, 5-HT and GABA may play a role in the manifestation of AD, MDD, BD and SZ. Among them are acetylcholine (for review see Koukouli and Maskos, 2015) , histamine (for a review see Shan et al., 2017) , glutamate (for a review see O'Donovan et al., 2017) , substance P (for a review see Nikolaus et al., 2013) and endocannabinoids (for a review see Campos et al., 2016) . Since, as of yet, the number of available in vivo imaging studies on these neurotransmitters is scarce, future efforts must also be directed towards elucidating their contributions to the pathophysiology of AD, MDD, BD and SZ. 
